chas_taylor

Ceryx Medical announce new chairman Chas Taylor

pharmafile | April 7, 2021 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Cardiovascular technology company Ceryx Medical have appointed Chas Taylor as their new chairman.

The appointment comes at an interesting time for the company, which is preparing for its first-in-man trials of its cardiac rhythm management device.

Ceryx Medical’s technology is able to alleviate the debilitating symptoms of heart failure and give the heart the opportunity to repair itself. Taylor has been appointed in order to further market the company and its new technology.

Taylor said, “Very few devices have captured my attention in the way this has. The Ceryx Medical technology has the potential to improve cardiac output and enhance cardiac repair in heart failure patients. Stuart [Plant] and the team have done an exceptional job so far, and I’m delighted to be associated with this exciting project.”

Dr Stuart Plant, Ceryx’s CEO, added: “This is a hugely exciting time for us, as we near the final and most important pre-commercialisation stage of our journey.”

Related Content

No items found

Latest content